Subretinal Fibrosis in Uveitis

Emmett T Cunningham Jr^{1

2

3}, Derrick P Smit⁴, Manfred Zierhut⁵

Affiliations

¹ The Department of Ophthalmology, California Pacific Medical Center, San Francisco, California, USA.
² The Department of Ophthalmology, Stanford University School of Medicine, Stanford, California, USA.
³ The Francis I. Proctor Foundation, UCSF School of Medicine, San Francisco, California, USA.
⁴ Division of Ophthalmology, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
⁵ Centre for Ophthalmology, University Tuebingen, Tuebingen, Germany.

Editorial

Emmett T Cunningham Jr et al. Ocul Immunol Inflamm. 2022.

. 2022 Feb 17;30(2):263-264.

doi: 10.1080/09273948.2022.2043079.

Emmett T Cunningham Jr^{1

2

3}, Derrick P Smit⁴, Manfred Zierhut⁵

¹ The Department of Ophthalmology, California Pacific Medical Center, San Francisco, California, USA.
² The Department of Ophthalmology, Stanford University School of Medicine, Stanford, California, USA.
³ The Francis I. Proctor Foundation, UCSF School of Medicine, San Francisco, California, USA.
⁴ Division of Ophthalmology, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
⁵ Centre for Ophthalmology, University Tuebingen, Tuebingen, Germany.

No abstract available

Comment on

Risk factors for subretinal fibrosis in patients with Vogt Koyanagi Harada syndrome.
Golzarri MF, Cheja-Kalb R, Concha-Del-Río LE, Gonzalez-Salinas R, Arellanes-García L. Golzarri MF, et al. Ocul Immunol Inflamm. 2022 Feb 17;30(2):265-269. doi: 10.1080/09273948.2020.1825750. Epub 2020 Oct 6. Ocul Immunol Inflamm. 2022. PMID: 33021860